KU Leuven Research & Development
Venture capitalPre-Seed
Investment thesis
CD3 combines drug discovery expertise with investment activity, focusing on translating innovative science from academic and biotech partners into new medicines. It collaborates with academic researchers and biotech/pharma companies on drug discovery projects, and invests in drug discovery spin-offs and biotechs. The fund aims to bridge the gap between early biomedical research and the pharmaceutical industry, creating value for all stakeholders while addressing significant unmet medical needs.
Source: firm website, verified Jul 30, 2026.
What they invest in
from 1 of 1 portfolio companiesAI & Machine Learning ×1Biotech ×1Medical Devices ×1
Investments · 1 tracked
founders shown can be your intro pathEnedra analyzes tumor evolution patterns by decoding convergent genomic signatures from cancer genomic data.
AI & Machine LearningBiotechMedical Devices
Co-investorsDeep Science VenturesO2h Ventures
Frequently asked questions
- What stage does KU Leuven Research & Development invest at?
- KU Leuven Research & Development invests at the Pre-Seed stage.
- What sectors does KU Leuven Research & Development focus on?
- KU Leuven Research & Development focuses on Biotech, Healthtech, Medical Devices.
Images
Similar investors
Sunstone Life Science Ventures is an independent European venture capital firm focused on early-stage life science companies developing novel therapeutics for humans.
Arboretum Ventures is a Midwest-based healthcare venture capital firm that invests in early-stage healthcare startups across medical devices, life science tools and diagnostics, tech-enabled care delivery, and pharma adjacencies.
Epidarex Capital is a transatlantic venture capital firm focused on early-stage life science companies, backing founders building businesses in emerging innovation hubs.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
Life Sciences Greenhouse Investments (LSGI) is an evergreen venture fund that provides early-stage capital and operational support to Pennsylvania life science companies working on drug discovery, diagnostics, devices, and healthcare IT solutions.